This funding supports investigator-initiated phase I clinical trials for diagnostic and therapeutic interventions addressing heart, lung, blood, and sleep disorders in adults and children. Trials can be single or multisite and require readiness to initiate within the first quarter of the project period, including regulatory approvals and drug supply establishment.
Eligible applicants include a wide range of organizations such as governments, higher education institutions, nonprofits, for-profits, tribal organizations, and small businesses. Non-domestic entities are not eligible, but foreign components of U.S. organizations are allowed.
